New book by Larry Connors Click here Improve your trading - See how
Visit Us On Twitter and Facebook: http://twitter.com/StandoutStocks http://www.facebook.com/people/Standout-Stocks/547603354
Sign-up for our FREE Stock Alerts AND AWARD WINNING NEWSLETTER at www.Standoutstocks.com
Jun 24, 2009 -- Gulf Resources, Inc. (OTCBB: GFRE | Quote | Chart | News | PowerRating) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced the resignation of Mr. Min Li as director of the Board of Directors, effective as of June 22, 2009.
Mr. Li resigned from the Board to devote more time to his duties as Chief Financial Officer of Gulf Resources. There were no disagreements between Mr. Li and the Company which resulted in his resignation.
Following the resignation of Mr. Li, the Company's Board of Directors has seven members, of which four are independent. Effective as of June 22, the Company also established a Nominating and Corporate Governance Committee comprised of independent directors Shi Tong Jiang, Ya Fei Ji, and Richard Khaleel and a Compensation Committee comprising of independent directors Shi Tong Jiang, Ya Fei Ji, and Biagio Vignolo. The Company's Audit Committee was established in October 2007 and is comprised of Shi Tong Jiang, Richard Khaleel, and Biagio Vignolo. Consequently, Gulf Resources' Board meets the corporate governance standards of a senior exchange.
"We want to thank Mr. Li for his contribution to our Board and wish to emphasize that we continue to benefit from his experience as he continues in his position as CFO," said Xiaobin Liu, Chief Executive Officer of Gulf Resources. "Now that our board is comprised of a majority of independent directors and we have established all required committees and adopted written charters for each, we aim to progress with our plans to list on a senior exchange."
About Gulf Resources, Inc.
Gulf Resources, Inc. operates through two wholly-owned subsidiaries, Shouguang City Haoyuan Chemical Company Limited ("SCHC") and Shouguang Yuxin Chemical Industry Co., Limited ("SYCI"). The Company believes that it is one of the largest producers of bromine in China. Elemental Bromine is used to manufacture a wide variety of compounds utilized in industry and agriculture. Through SYCI, the Company manufactures chemical products utilized in a variety of applications, including oil & gas field explorations and as papermaking chemical agents.
Jun 25, 2009 -- Helix Wind, Corp. (OTCBB: HLXW | Quote | Chart | News | PowerRating) has signed a binding Letter of Intent to acquire VENCO Power GmbH of Germany. The total purchase price of VENCO will depend on the value of the Euro at closing and will range from 2.75MM to 3MM EUR in cash and restricted common stock of Helix Wind, Corp. The acquisition of VENCO will bring 15 years of vertical axis wind turbine development and experience and broaden the product portfolio of Helix Wind by providing 3 additional small wind turbines to complement Helix Wind's existing vertical axis solutions, the S322 and S594. Helix Wind will now offer two technology types of vertical axis wind turbines, Savonius and Darrieus, which complement each other for different types of vertical market solutions. Helix Wind will start selling the D100, D361, and D15000 models from VENCO immediately. The benefit of having two technology types of vertical axis products will enable our distributors to support a wider range of customer requirements in many vertical markets with different price points and levels of performance output. Inorganic acquisition growth allows Helix Wind to continue executing its business plan by being product, market, and solution agnostic in the expansion of needed small wind solutions. In addition, the acquisition provides extensive development experience to add additional headcount and engineering talent to Helix Wind's existing team. The acquisition will occur when, among other conditions, Helix Wind obtains audited financial statements of VENCO Power as required by SEC rules.
Helix Wind CEO Ian Gardner commented, "The nature of inorganic growth through acquisition to purchase VENCO Power GmbH allows Helix Wind, Corp. to continue executing on its business plan to more accurately reflect global solution based small wind needs by providing the best technologies within a small wind vertical axis product line. This completes the next phase in the development and execution of our product portfolio to provide agnostic solutions internationally and to position the company as a broader partner in solving renewable energy challenges."
Reinhard Caliebe of VENCO Power GmbH commented, "The sale of VENCO Power will benefit the shareholders of both companies by providing the best of vertical axis wind turbines under one company, Helix Wind. With VENCO's 15 years of extensive product development in Darrieus vertical axis small wind products, it is best served to provide both technologies within a single product portfolio for broader market coverage and solution selling. We are very pleased to be announcing this strategic Letter of Intent with Helix Wind to deliver the best of European and American development together resulting in multiple platforms and solutions."
About Helix
Helix Wind is a global renewable energy company. Helix Wind is engaged in the design, manufacturing and sale of small wind vertical axis turbines designed to generate 300W, 1kW, 2.0kW, 4.5kW, and 50kW of clean, renewable electricity.
About VENCO
VENCO Power GmbH is a global renewable energy company. VENCO Power is engaged in the design, manufacturing and sale of small wind vertical axis turbines designed to generate 0.3, 1.0 and 50.0 kW of clean, renewable electricity.
Jun 25, 2009 -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (NASDAQ: MNOV | Quote | Chart | News | PowerRating) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), and Avigen, Inc. (NASDAQ: AVGN), a biopharmaceutical company, today announced that they have confirmed their understanding of certain key terms for a proposed acquisition of Avigen by MediciNova that would combine the companies' broad neurological clinical development programs based on ibudilast (Avigen's AV-411 and MediciNova's MN-166).
MediciNova and Avigen currently contemplate that the terms of the merger would provide that Avigen shareholders receive consideration approximating Avigen's net cash liquidation value plus $3 million. Avigen shareholders would be able to elect to receive this consideration in cash at closing or to receive a convertible security by which that cash consideration may be converted into MediciNova stock at a conversion price equal to the greater of $4.00 or a mutually agreeable volume-weighted average price of MediciNova common stock. At the end of 18 months, any unexercised convertible securities would be paid out at their cash value. This would allow shareholders of both companies the opportunity to participate in the future value created by combining the companies' product portfolios. In addition to the consideration above, all Avigen shareholders would receive a contingent payment right for a specific product program milestone payment associated with Avigen's Assignment Agreement with Genzyme Corporation, potentially subject to certain adjustments.
Yuichi Iwaki, M.D., Ph.D., MediciNova's President and Chief Executive Officer, said, "We are excited to announce this important step towards a potential acquisition of Avigen and believe that the proposed merger presents clear advantages for the shareholders of both companies, most notably, the ability to more fully take advantage of the opportunities that the ibudilast compound and analogs provide in a variety of indications and markets. We look forward to finalizing definitive documentation as expeditiously as possible and to presenting this transaction for shareholder approval in due course."
"Avigen believes the proposed merger on the terms currently contemplated would be in the best interests of our shareholders and we intend to continue to negotiate with the goal of reaching agreement on all of the terms and presenting it to our shareholders for approval in the third quarter of 2009," commented Andrew Sauter, Avigen's Chief Executive Officer, President and Chief Financial Officer. "We believe that combining our ibudilast programs, AV411 and MN-166, would enhance the global development potential for the compound in a range of neurological indications, including Multiple Sclerosis, neuropathic pain and drug addiction."
The understanding reached by the parties is nonbinding and subject to definitive documentation and due diligence. The closing of any proposed merger would also be subject to customary closing conditions, including required shareholder and regulatory approvals and the absence of material adverse changes. MediciNova and Avigen are not legally obligated to continue discussions regarding the proposed transaction on the terms described herein or on any other terms. No definitive agreements have been reached, and there can be no assurances that definitive agreements will be successfully negotiated, that the proposed terms will not be revised or that the proposed merger will be completed.
About MediciNova
MediciNova, Inc. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova's pipeline includes six clinical-stage compounds for the treatment of acute exacerbations of asthma, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova's current strategy is to focus its resources on its two prioritized product candidates, MN-221 for the treatment of acute exacerbations of asthma and MN-166 for the treatment of multiple sclerosis, and either pursue development independently, in the case of MN-221, or establish a strategic collaboration to support further development, in the case of MN-166. MediciNova will seek to monetize its other product candidates at key value inflection points.
Jun 25, 2009 -- Universal Detection Technology (OTCBB: UNDT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats and provider of counter-terrorism consulting and training services, reported today that it has been awarded a North Atlantic Treaty Organization (NATO) CAGE Number for its biological weapon detection systems. The CAGE code allows for marketing of the instruments to NATO affiliated countries.
The NATO Commercial and Government Entity, or NCAGE, code is a five-character ID number that identifies government contractors. NCAGE codes are an important part for companies winning contracts with NATO affiliated countries. The UDT CAGE/NCAGE code is: 1WLU0. UNDT is now listed along with all U.S. and NATO companies with a CAGE/NCAGE Code. The code lists UNDT in a primary vendor database for the U.S. Federal Government and is used as a government tool for the Department of Homeland Security, Department of Defense, NATO and NASA Agencies. Having this information immediately available allows the U.S. Government and NATO countries to rapidly find the companies with the right capabilities to offer services for required government initiatives, including research & development projects, particular supply needs, up to a pandemic alert requirement or other emergency requirements.
"The awarding of our NCAGE code is a significant step for us to market our equipment to a rapidly expanding NATO alliance that has significant biological weapon detection needs," said Mr. Jacques Tizabi, UNDT's Chief Executive Officer.
About Universal Detection Technology
Universal Detection Technology is a developer of monitoring technologies, including bioterrorism detection devices. The Company on its own and with development partners is positioned to capitalize on opportunities related to Homeland Security. For example, the Company, in cooperation with NASA, has developed a bacterial spore detector that detects certain biohazard substances. The Company is also a reseller of handheld assays used for detection of five bioterrorism agents, radiation detection systems, and antimicrobial products.
About Standoutstocks.com
Standoutstocks.com has become one of the premier stops for investors who wish to experience huge profits via investing in up-and-coming publicly traded companies.
Standoutstocks.com email report service is free to those investors who sign up on our website. The alert service is designed to notify investors of undervalued and often overlooked stocks. Subscribers are introduced to OTCBB and Pinksheet companies that have the potential of showing increased activity and Standing Out from the rest of the market. To subscribe to this free service, visit the Standout StocksReport home page at www.Standoutstocks.com and select the "join now" button.
Join us at www.standoutstocks.com for a complimentary subscription to the most exciting online financial newsletter on the market.
Disclaimer: Verify all claims and do your own due diligence. Standoutstocks.com profiles are not a solicitation or recommendation to buy, sell or hold securities. Standoutstocks.com is not offering securities for sale. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. All statements and expressions are the sole opinion of the editor and are subject to change without notice. Standoutstocks.com is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. It should be understood there is no guarantee that past performance will be indicative of future results. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. In order to be in full compliance with the Securities Act of 1933, Section 17(b), Standoutstocks.com is owned and operated by Standoutstocks.com. Neither Standoutstocks.com nor any of its affiliates, or employees shall be liable to you or anyone else for any loss or damages from use of this e-mail, caused in whole or part by its negligence or contingencies beyond its control in procuring, compiling, interpreting, reporting, or delivering this Web Site or e-mail and any contents. Since Standoutstocks.com receives compensation and its employees or members of their families may hold stock in the profiled companies, there is an inherent conflict of interest in Standoutstocks.com statements and opinions and such statements and opinions cannot be considered independent. Standoutstocks.com and its management may benefit from any increase in the share prices of the profiled companies. Information contained herein contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be "forward looking statements". Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Standoutstocks.com services are often paid for using free-trading shares. Standoutstocks.com may be selling shares of stock at the same time the profile is being disseminated to potential investors; this should be viewed as a definite conflict of interest and as such, the reader should take this into consideration.
Visit us for a full Disclaimer at: www.standoutstocks.com/disclaimer.aspx
For More Information Regarding Standout Stocks, Contact Jason A. Hilton: Rochester, Ny 14609 Office: (866)704-0122 Email: Jason@Newmediaadvisorsllc.com
CONTACT: Jason A. Hilton, New Media Advisors LLC Tel: +1 866 704 0122 e-mail: Jason@Newmediaadvisorsllc.com Standoutstocks.com e-mail: info@standoutstocks.com WWW: http://www.standoutstocks.com
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
